Alnylam Pharmaceuticals | ALNY - Current Assets


Alnylam Pharmaceuticals reported $4.22B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Moderna USD 5.77B 774M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Takeda JPY 3.09T 25.94B Mar/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026